Cardiac resynchronisation therapy for heart failure

Area of Science:

• Cardiology
• Medical Devices

Background:

• Chronic heart failure (CHF) with left ventricular systolic dysfunction and prolonged QRS duration impacts patient outcomes.
• Cardiac resynchronisation therapy (CRT) is an established treatment for select CHF patients.

Observation:

• Recent studies indicate CRT reduces mortality in CHF patients.
• Combining CRT with an implantable cardioverter defibrillator (ICD) may offer additional mortality benefits.
• CRT is generally well-tolerated and bypasses compliance issues.

Findings:

• CRT improves left ventricular function and reduces symptoms in CHF patients.
• Evidence suggests CRT significantly reduces mortality, with potential for greater reduction when combined with an ICD.
• Identifying optimal candidates for CRT is crucial for maximizing benefits and has health economic implications.

Implications:

• CRT should be strongly considered for all eligible CHF patients due to its tolerability and efficacy.
• Further research is needed to identify patient subgroups who will benefit most from CRT.
• The use of an intra-aortic balloon pump as a bridge to CRT in end-stage heart failure is a viable therapeutic strategy.